BiotechTube

Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mutant IDH1 Inhibitor Olutasidenib

Conditions

Mutant IDH1 Inhibitor Olutasidenib

Trial Timeline

Aug 29, 2024 → Jun 30, 2029

NCT ID
NCT06445959

About Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine

Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine is a phase 1/2 stage product being developed by Rigel Pharmaceuticals for Mutant IDH1 Inhibitor Olutasidenib. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06445959. Target conditions include Mutant IDH1 Inhibitor Olutasidenib.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06445959Phase 1/2Recruiting

Competing Products

20 competing products in Mutant IDH1 Inhibitor Olutasidenib

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
erlotinibAstellas PharmaPhase 1
33
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
77
encorafenib + Binimetinib + CetuximabOno PharmaceuticalPhase 2
52
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for InfusionJiangsu Hengrui MedicinePhase 1/2
41
HRS-6093Jiangsu Hengrui MedicinePhase 1
33
famitinib po + HS-10296 poJiangsu Hengrui MedicinePhase 2
52
Pyrotinib maleateJiangsu Hengrui MedicinePre-clinical
23
HRS-4642Jiangsu Hengrui MedicinePhase 1
33
HRS-4642 + AG + HRS-4642 placebo + AGJiangsu Hengrui MedicinePhase 3
77
Tremelimumab + DurvalumabAstraZenecaPhase 2
52
AvelumabMerckPhase 3
77
TNO155 + TNO155 in combination with EGF816 (nazartinib)NovartisPhase 1
33
BKM120 Combined with Vemurafenib (PLX4032)NovartisPhase 1/2
41
JDQ443 + TNO155 + tislelizumabNovartisPhase 1/2
41
JDQ443 + trametinib + Ribociclib + cetuximabNovartisPhase 1/2
41
AEB071 + EverolimusNovartisPhase 1
33
EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinibNovartisPhase 1
33
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + PemetrexedRochePhase 2
52
sotorasib + Anti PD-1/L1 + MidazolamAmgenPhase 1/2
40

Other Products from Rigel Pharmaceuticals

Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesApproved
77
Fostamatinib Disodium + PlaceboPhase 3
69
Fostamatinib disodiumPhase 3
69
Fostamatinib DisodiumPhase 3
69
Fostamatinib + PlaceboPhase 3
69